Nanoviricides, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by BONIUK MILTON, was filed 17 Nov 2015.
Nanoviricides, Inc.: what insiders have been doing
Nanoviricides, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for Nanoviricides, Inc. The previous disclosure was published on 10 August 2022.
Over the whole record (from 2008), the tally stands at 62 purchases and 172 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 30 June 2026), the company reported net income of -8.2 m USD.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Since the insiders bought
- +12.3%Entry US$22.80 · Close at T+365 US$25.60
- -53.3%Entry US$51.40 · Close at T+365 US$24.00
- -71.6%Entry US$73.20 · Close at T+365 US$20.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Nanoviricides, Inc. Strong Buy (bullish), based on 2 analysts. Average price target: US$6.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
- 94,471 shares0Common Stock, par value $0.001 per shareSEC:0001140361-22-029132:0
- 5,500,000 sharesCommon Stock, par value $0.001 per shareSEC:0001214659-18-006488:4
- 1,746,288 sharesCommon Stock, par value $0.001 per shareSEC:0001214659-18-006488:0
- 153,611 sharesCommon Stock, par value $0.001 per shareSEC:0001214659-18-006488:1
- 149,478 sharesCommon Stock, par value $0.001 per shareSEC:0001214659-18-006488:2
- 120,744 sharesCommon Stock, par value $0.001 per shareSEC:0001214659-18-006488:3
- 605,474 shares0Common Stock, par value $0.001 per shareSEC:0001144204-17-005838:0
- 25,000 shares@ US$1.5021.4% of flowCommon Stock, par value $0.001 per shareSEC:0001144204-16-104385:0
- 14,991 shares@ US$1.6814.0% of flowCommon Stock, par value $0.001 per shareSEC:0001144204-16-103281:0
- 25,000 shares@ US$1.5021.1% of flowCommon Stock, par value $0.001 per shareSEC:0001144204-16-103281:1
- 7,109 shares@ US$1.686.7% of flowCommon Stock, par value $0.001 per shareSEC:0001144204-16-099213:0
- 2,900 shares@ US$1.682.7% of flowCommon Stock, par value $0.001 per shareSEC:0001144204-16-099213:1
- 25,000 shares@ US$1.7825.2% of flowCommon Stock, par value $0.001 per shareSEC:0001144204-16-098303:0
- 9,000 shares@ US$1.708.8% of flowCommon Stock, par value $0.001 per shareSEC:0001144204-16-084125:0
- 9,000 sharesCommon Stock, par value $0.001 per shareSEC:0001144204-16-082885:0
- 9,000 sharesCommon Stock, par value $0.001 per shareSEC:0001144204-16-082885:1
- 34,043 sharesCommon Stock, par value $0.001 per shareSEC:0001144204-16-082885:2
- 34,043 sharesCommon Stock, par value $0.001 per shareSEC:0001144204-16-082885:3
- 141,844 sharesCommon Stock, par value $0.001 per shareSEC:0001144204-16-082885:4
- 25,000 shares@ US$1.20Common Stock, par value $0.001 per shareSEC:0001144204-15-066271:0Canonical exit: 9 Feb 2016 (T+90)
- 2,200 shares@ US$1.30Common Stock, par value $0.001 per shareSEC:0001144204-15-060613:0Canonical exit: 13 Jan 2016 (T+90)
- 2,958 shares@ US$1.30Common Stock, par value $0.001 per shareSEC:0001144204-15-060613:1Canonical exit: 17 Jan 2016 (T+90)
- 5,202 shares@ US$1.30Common Stock, par value $0.001 per shareSEC:0001144204-15-060613:2Canonical exit: 19 Jan 2016 (T+90)
- 14,640 shares@ US$1.30Common Stock, par value $0.001 per shareSEC:0001144204-15-060613:3Canonical exit: 20 Jan 2016 (T+90)
- 208,771 shares@ US$0.35Common Stock, par value $0.001 per shareSEC:0001140361-15-035881:0
25 of 261 declarations
About Nanoviricides, Inc.
Nanoviricides, Inc. is a company focused on developing antiviral treatments based on nanotechnology. It is listed on the XNAS market.
